This Is MS Multiple Sclerosis Community: Knowledge & Support

A double-blind, placebo-controlled trial of a new veno-active flavonoid fraction (S 5682) in the treatment of symptomatic capillary fragility.

The efficacy and safety of a new veno-active flavonoid fraction (S 5682) consisting of micronized diosmin (90%) and hesperidin (10%) have been studied in 100 patients with symptomatic capillary fragility in a double-blind, randomized, placebo-controlled trial. Treatment lasted 6 weeks and consisted of 2 daily tablets of either S 5682 or placebo. Patients were examined at weeks 0, 2, 4, and 6. Compared to placebo, capillary resistance, assessed by the negative suction cup method, was significantly higher in the S 5682 group at week 4 (219 +/- 10 mmHg versus 159 +/- 8 mmHg; p < 0.001) and week 6 (261 +/- 12 mmHg versus 163 +/- 9 mmHg; p < 0.001). This resulted in a significant improvement of symptoms of capillary fragility (spontaneous ecchymosis, epistaxis, purpura, petechiae, gingivorrhagia, metrorrhagia and conjunctival haemorrhage) in S 5682 treated patients (p < 0.001). S 5682 was well tolerated. The rate of side-effects spontaneously volunteered by the patients was similar in both groups. We, therefore, conclude that S 5682 increases to a large extent the capillary resistance in patients with abnormal capillary fragility without significant side-effects.

A Thapar, TRA Lane, V Pandey, J Shalhoub… - …, 2011 - phleb.rsmjournals.com
... prior venography revealed a short segment stenosis at the junction of the left internal jugular and brachiocephalic veins that had been venoplastied with a 10 x 40 mm balloon at 10 atmospheres. Postoperatively she received dagibatran 220 mg, aspirin 100 mg and daflon 1 ...

Internal jugular thrombosis post venoplasty for chronic cerebrospinal venous insufficiency
http://www.phleb.rsmjournals.com/conten ... 4.abstract

Abstract

Chronic cerebrospinal venous insufficiency (CCSVI) is a hypothesis through which cerebral venous drainage abnormalities contribute towards the pathogenesis of multiple sclerosis. CCSVI venoplasty is already practised worldwide. We report the case of a 33-year-old lady with multiple sclerosis who underwent left internal jugular venoplasty resulting in iatrogenic jugular thrombosis requiring open thrombectomy for symptom relief. This occurred without insertion of a stent and while fully anticoagulated. Clinicians should be aware that endovenous treatment of CCSVI could cause paradoxical deterioration of cerebral venous drainage. Patients with complications post venoplasty are now presenting to geographically distant vascular units.

The Google Scholar Search Results Page for the search terms 'daflon' and 'jugular' shows this information in the first hit:


I really wanted to know why she was given Daflon after her IJV thrombectomy, so I clicked on the link and was sent to the abstract of the September, 2011, issue of Phlebology; unfortunately, the abstract didn't discuss Daflon. Does anyone have access to the full text of the study?

The patient in that article is a TIMSer. She might know.

chronic-cerebrospinal-venous-insufficiency-ccsvi-f40/topic17442.html#p172238

Question for readers of the thread:
Why would Google be able to retrieve and show text that includes the word "Daflon" and other text (e.g., short segment), but the word and other text doesn't show on the public abstract page at the Phlebology site??? Why/how can Google see more than we can see? Hope this makes sense!

Thanks for jogging my memory, Cece. I wonder if she was given Daflon to help control bleeding in her context? What's your guess? I do hope she'll see these posts and will answer some of our questions.

Perhaps there is more than one role for Daflon: 1) to help control bleeding via vasoconstriction, 2) to help inhibit leukocytes, 3) to decrease valvular remodeling, and 4) to help inhibit "capillaries from leaching their contents into our brains" via vasoconstriction (Jugular's last post).

Chris was treated in Tokuda by dr Petrov one day after i was. I was prescribed a 3 month regime of Plavix (which ended the day before yesterday) and a 6 month regime of Daflon and baby aspirin.